

DAFTAR PUSTAKA

1. Depkes RI. 2013. Riset Kesehatan Dasar. Jakarta: Badan Penelitian dan pengembangan Kesehatan Kementerian Kesehatan RI.
2. Torpy JM, Lynn C, Glass RM. Percutaneous coronary intervention. *JAMA*. 2004;291(6):778. doi:10.1001/jama.291.6.778.
3. Tehrani S, Laing C, Yellon DM, Hausenloy DJ (2013) Contrast-induced acute kidney injury following PCI. *Eur J Clin Invest* 43:483–490
4. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. *Am J Kidney Dis* 2002;39:930–6.
5. Scheller B. How to protect from contrast media-induced nephropathy? *Clin Res Cardiol* 2007;96:125–9.
6. Blackman DJ, Pinto R, Ross JR, Seidelin PH, Ing D, Jackevicius C et al. Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. *Am Heart J* 2006;151:146–52.
7. Lindsay J, Apple S, Pinnow EE, Gevorkian N, Gruberg L, Satler LF et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. *Catheter Cardiovasc Interv* 2003;59:338–43.
8. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F et al. Epidemiology and prognostic implications of contrast-induced nephropathy. *Am J Cardiol* 2006;98:5K–13K.
9. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation* 2002;105:2259–64.
10. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med* 1997;103:368–75.
11. Ziogiannis P, Rentoukas E, Lazaros G. Contrast media induced nephropathy in patients undergoing catheterisation. *Hellenic J Cardiol*. 2004; 45:107-13.
12. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. *Catheter Cardiovasc Interv* 2001;52:409–16.
13. Yuniadi Y, Ningrum NR. Risk factors and incidence of contrast induced nephropathy following coronary intervention. *Med J Indones*. 2008; 17: 131-6.
14. Stacul F, Van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. *Eur Radiol* 2011;21:2527–41.
15. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. *N Engl J Med* 1989;320:143–9.
16. Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. *N Engl J Med* 1989;320:149–53.
17. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. *CMAJ* 2005;172:1461–71.

18. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. *J Am Coll Cardiol*. 2004;44(7):1393-1399. doi:10.1016/j.jacc.2004.06.068.
19. Morcos SK. Prevention of contrast media nephrotoxicity—the story so far. *Clin Radiol* 2004;59:381–9.
20. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. *AJR Am J Roentgenol* 2003;181: 1463–71.
21. Caixeta A, Mehran R. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. *Catheter Cardiovasc Interv* 2010;75(Suppl. 1):S15–20.
22. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. *AJR Am J Roentgenol* 2004;183:1673–89.
23. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. *Mayo Clin Proc* 2004;79:211–9.
24. Katzberg RW. Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity. *Radiology*. 1997; 204: 297–312.
25. Davidson CJ, Hlatky M, Morris KG, dkk. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. *Ann Intern Med*. 1989; 110: 119-24.
26. Aspelin P, Aubry P, Franssen SG. Nephrotoxic effects in high risk patients undergoing angiography. *N Eng J Med*. 2003; 6: 491-9.
27. Tsai TT, Patel UD, Chang TI, et al. Contemporary Incidence, Predictors, and Outcomes of Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions: Insights From the NCDR Cath-PCI Registry. *JACC Cardiovascular interventions*. 2014;7(1):1-9. doi:10.1016/j.jcin.2013.06.016.
28. James MT, Samuel SM, Manning MA, et al: Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: A systematic review and meta-analysis. *Circ cardiovasc Interv* 6:37, 2013.
29. McCullough PA. Contrast-induced acute kidney injury. *J Am Coll Cardiol* 2008; 51:1419-28.
30. Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cytotoxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. *Radiology* 2005;235:843–9.
31. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. *Acta Radiol* 2008;49:646–57.
32. Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. *Eur Heart J* 2012;33:2007–15.
33. McCullough P. Outcomes of contrast-induced nephropathy: experience in patients undergoing cardiovascular intervention. *Catheter Cardiovasc Interv* 2006;67:335–43.
34. Almen T. Visipaque—a step forward. A historical review. *Acta Radiol Suppl* 1995;399:2–18.
35. Sana Shoukat, Saqib A. Gowani, Asif Jafferani, and Sajid H. Dhakam, “Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention,” *Cardiology Research and Practice*, vol. 2010, Article ID 649164,

- 12 pages, 2010. doi:10.4061/2010/649164.
36. Meschi M, Detrenis S, Musini S, Strada E, Savazzi G. Facts and fallacies concerning the prevention of contrast medium-induced nephropathy. *Crit Care Med* 2006;34:2060–8.
 37. P. B. Persson, P. Hansell, and P. Liss, “Pathophysiology of contrast medium-induced nephropathy,” *Kidney International*, vol. 68, no. 1, pp. 14–22, 2005.
 38. Baars T, Kleinbongard P, Bose D, Konorza T, Mohlenkamp S, Hippler J et al. Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential. *Basic Res Cardiol* 2012;107:303.
 39. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. *Kidney Int* 1995;47:254–61.
 40. G. Dangas, I. Iakovou, E. Nikolsky et al., “Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables,” *American Journal of Cardiology*, vol. 95, no. 1, pp. 13–19, 2005.
 41. Marenzi, G. Lauri, E. Assanelli et al., “Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction,” *Journal of the American College of Cardiology*, vol. 44, no. 9, pp. 1780–1785, 2004.
 42. Wickenbrock I, Perings C, Maagh P, Quack I, van BM, Prull MW et al. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. *Clin Res Cardiol* 2009;98:765–72.
 43. Alamartine E, Phayphet M, Thibaudin D, Barral FG, Veyret C. Contrast medium-induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations. *Eur J Intern Med* 2003;14:426–31.
 44. B. J. Barrett and E. J. Carlisle, “Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media,” *Radiology*, vol. 188, no. 1, pp. 171–178, 1993.
 45. C. M. Erley, “Does hydration prevent radiocontrast-induced acute renal failure?” *Nephrology Dialysis Transplantation*, vol. 14, no. 5, pp. 1064–1066, 1999.
 46. Goldfarb S, McCullough PA, McDermott J, et al: Contrast-induced acute kidney injury: Specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional radiology. *Mayo Clin Proc* 84:2,2009.
 47. Marenzi G, Ferrari C, Marana I, et al: Prevention of contrast nephropathy for furosemide with matched hydration: The MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. *JACC Cardiovasc Interv* 5:1, 2012.
 48. Stacul F, van der Molen AJ, Reimer P, et al: Contrast Induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. *Eur Radiol* 21:12, 2011.
 49. Libby PP, Bonow RO, Mann DL, Zipes DP. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 8th edition. Philadelphia: Elsevier Science, 2007.

50. J. DiMari, J. Megyesi, N. Udvarhelyi, P. Price, R. Davis, and R. Safirstein, "N-acetyl cysteine ameliorates ischemic renal failure," *American Journal of Physiology*, vol. 272, no. 3, pp. F292–F298, 1997.
51. M. Tepel, M. Van Der Giet, C. Schwarzfeld, U. Laufer, D. Liermann, and W. Zidek, "Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine," *New England Journal of Medicine*, vol. 343, no. 3, pp. 180–184, 2000.
52. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al SA et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. *Am Heart J* 2004;148:422–9.
53. G. Patti, A. Nusca, M. Chello et al., "Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention," *American Journal of Cardiology*, vol. 101, no. 3, pp. 279–285, 2008.
54. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von BC et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. *Circulation* 2002;106:2180–3.
55. A. Toso, M. Maioli, M. Leoncini et al., "Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease," *American Journal of Cardiology*, vol. 105, no. 3, pp. 288–292, 2010.
56. Tublin ME, Murphy ME, Tessler FN. Current concepts in contrast media-induced nephropathy. *Am J Radiol*.1998; 171:933-9.
57. Bettmann MA. Contrast medium-Induced Nephropathy : critical review of the existing clinical evidence. *Nephrol Dial Transplant*. 2005; 20 (suppl 1): i12-7.
58. Berns J, Rudnick M. Radiocontrast media associated nephrotoxicity. *Kidney*. 1992; 24: 1-5.
59. Kolonko A, Kokot F, Wiecek A. Contrast –associated nephropathy-old clinical problem and new therapeutic perspectives. *Nephrol Dial Transplant*. 1998; 13: 803-6.
60. American Diabetes Association: *Diabetes Care* 37(Suppl 1):514,2014.
61. Nutritional anemias: report of a WHO Scientific Group. Geneva: World Health Organization, 1968.
62. Bolognese, Leonardo et al. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (From the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial). *American Journal of Cardiology* , Volume 109 , Issue 1 , 67 – 74.